San Diego, California-based Contineum Therapeutics Inc., has priced its initial public offering of 6.875 million shares of Class A common stock at $16.00 per share.
Founded in 2009, Contineum Therapeutics is a clinical stage biopharmaceutical company developing novel, oral small molecule therapies for the treatment of neuroscience, inflammation, and immunology (NI&I) indications.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com